Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome
Jia Xu; Priya B. Shetty; Weiwei Feng; Carol Chenault; Robert C. Bast Jr; Jean-Pierre J. Issa; Susan G. Hilsenbeck; Yinhua Yu (Profiled Author: Robert C Bast Jr)
BMC Cancer. 2012;12.Abstract
Background: Aberrant promoter CpG island hypermethylation is associated with transcriptional silencing. Tumor suppressor genes are the key targets of hypermethylation in breast cancer and therefore may lead to malignancy by deregulation of cell growth and division. Our previous pilot study with pairs of malignant and normal breast tissues identified correlated methylation of two pairs of genes - HIN-1/RASSFIA and RIL/CDH13 - with expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 (HER2). To determine the impact of methylation on clinical outcome, we have conducted a larger study with breast cancers for which time to first recurrence and overall survival are known.Methods: Tumors from 193 patients with early stage breast cancer who received no adjuvant systemic therapy were used to analyze methylation levels of RIL, HIN-1, RASSF1A and CDH13 genes for associations with known predictive and prognostic factors and for impact on time to first recurrence and overall survival.Results: In this study, we found that ER was associated with RASSF1A methylation (p < 0.001) and HIN-1 methylation (p = 0.002). PR was associated with RIL methylation (p = 0.012), HIN-1 (p = 0.002), and RASSF1A methylation (p = 0.019). Tumor size was associated with RIL and CDH13 methylation (both p = 0.002), and S-phase was associated with RIL methylation (p = 0.036). Only RASSF1A was associated with worse time to first recurrence (p = 0.045) and worse overall survival (p = 0.016) after adjusting for age, tumor size, S-phase, estrogen receptor and progesterone receptor.Conclusions: Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancers was associated with clinical characteristics, but only RASSF1A methylation was associated with time to first recurrence and overall survival. Our data suggest that RASSF1A methylation could be a potential prognostic biomarker. © 2012 Xu et al.; licensee BioMed Central Ltd.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
De-Yuan Fu; Zhi-Min Wang; Bei-Lan Wang; Li Chen; Wen-Tao Yang; Zhen-Zhou Shen; Wei Huang; Zhi-Ming ShaoHuman Pathology. 2010;41(1):48-58.
Guillermo Garcia-Manero; Carlos Bueso-Ramos; Jerry Daniel; Jason Williamson; Hagop M. Kantarjian; Jean-Pierre J. IssaClinical Cancer Research. 2002;8(6):1897-1903.
Weiwei Feng; Lanlan Shen; Sijin Wen; Daniel G. Rosen; Jaroslav Jelinek; Xin Hu; Shaoyi Huan; Miao Huang; Jinsong Liu; Aysegul A. Sahin; et al.Breast Cancer Research. 2007;9(4).
Appears in this Document